PDB36 LONG-TERM Cost-Effectiveness Analyses of Once-Weekly Semaglutide 1 MG Versus Empagliflozin 25 MG for Treatment of Type 2 Diabetes in Three Countries: Bosnia and Herzegovina, Greece, and Slovenia

Authors :: N. Hallén
S. Liatis
A. Thanopoulou
A. Ogrič Lapajne
I. Ioannidis
D. Djekic
B. Hunt
Source :: Value in Health. 23:S512
Publication Year :: 2020
Publisher :: Elsevier BV, 2020.

Subjects :: Cost effectiveness
business.industry
Health Policy
Semaglutide
Public Health, Environmental and Occupational Health
Empagliflozin
medicine
Once weekly
Type 2 diabetes
medicine.disease
business
Term (time)
Demography

Tools